Chemomab Therapeutics Ltd - ADR Stock
Chemomab Therapeutics Ltd - ADR Stock price
Key metrics
| Market capitalization | $24.99m |
| Enterprise Value | $12.55m |
| P/E (TTM) P/E ratio | negative |
| P/B ratio (TTM) P/B ratio | 2.50 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-16.09m |
| Cash position | $12.80m |
| EPS (TTM) EPS | $-1.14 |
| P/E forward | negative |
Is Chemomab Therapeutics Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
Chemomab Therapeutics Ltd - ADR Stock Analysis
Analyst Opinions
3 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:
Analyst Opinions
3 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:
Financial data from Chemomab Therapeutics Ltd - ADR
| Jun '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.06 -0.06 |
0%
0%
|
|
| EBITDA | -16 -16 |
53%
53%
|
EBIT (Operating Income) EBIT | -16 -16 |
53%
53%
|
| Net Profit | -15 -15 |
54%
54%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Chemomab Therapeutics Ltd - ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Chemomab Therapeutics Ltd - ADR Stock News
Company Profile
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.
| Head office | United States |
| CEO | Adi Mor |
| Employees | 20 |
| Founded | 2011 |
| Website | www.chemomab.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
